354 related articles for article (PubMed ID: 19346160)
1. A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.
Hajak G; Hedner J; Eglin M; Loft H; Stórustovu SI; Lütolf S; Lundahl J;
Sleep Med; 2009 Aug; 10(7):705-12. PubMed ID: 19346160
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.
Walsh JK; Mayleben D; Guico-Pabia C; Vandormael K; Martinez R; Deacon S
Sleep Med; 2008 May; 9(4):393-402. PubMed ID: 17765013
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
4. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem.
Leufkens TR; Lund JS; Vermeeren A
J Sleep Res; 2009 Dec; 18(4):387-96. PubMed ID: 19552733
[TBL] [Abstract][Full Text] [Related]
5. Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia.
Lundahl J; Staner L; Staner C; Loft H; Deacon S
Psychopharmacology (Berl); 2007 Nov; 195(1):139-46. PubMed ID: 17653697
[TBL] [Abstract][Full Text] [Related]
6. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study.
Dorsey CM; Lee KA; Scharf MB
Clin Ther; 2004 Oct; 26(10):1578-86. PubMed ID: 15598474
[TBL] [Abstract][Full Text] [Related]
7. Eight weeks of non-nightly use of zolpidem for primary insomnia.
Walsh JK; Roth T; Randazzo A; Erman M; Jamieson A; Scharf M; Schweitzer PK; Ware JC
Sleep; 2000 Dec; 23(8):1087-96. PubMed ID: 11145323
[TBL] [Abstract][Full Text] [Related]
8. Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies.
Lankford DA; Corser BC; Zheng YP; Li Z; Snavely DB; Lines CR; Deacon S
Sleep; 2008 Oct; 31(10):1359-70. PubMed ID: 18853933
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia.
Roger M; Attali P; Coquelin JP
Clin Ther; 1993; 15(1):127-36. PubMed ID: 8458042
[TBL] [Abstract][Full Text] [Related]
10. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
Roth T; Seiden D; Sainati S; Wang-Weigand S; Zhang J; Zee P
Sleep Med; 2006 Jun; 7(4):312-8. PubMed ID: 16709464
[TBL] [Abstract][Full Text] [Related]
11. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of indiplon in older adults with primary insomnia.
Walsh JK; Moscovitch A; Burke J; Farber R; Roth T
Sleep Med; 2007 Nov; 8(7-8):753-9. PubMed ID: 17825616
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Scharf MB; Roth T; Vogel GW; Walsh JK
J Clin Psychiatry; 1994 May; 55(5):192-9. PubMed ID: 8071269
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
Walsh JK; Soubrane C; Roth T
Am J Geriatr Psychiatry; 2008 Jan; 16(1):44-57. PubMed ID: 18165461
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial.
Lydiard RB; Lankford DA; Seiden DJ; Landin R; Farber R; Walsh JK
J Clin Sleep Med; 2006 Jul; 2(3):309-15. PubMed ID: 17561543
[TBL] [Abstract][Full Text] [Related]
16. Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients.
Monti JM; Attali P; Monti D; Zipfel A; de la Giclais B; Morselli PL
Pharmacopsychiatry; 1994 Jul; 27(4):166-75. PubMed ID: 7972349
[TBL] [Abstract][Full Text] [Related]
17. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study.
Voshaar RC; van Balkom AJ; Zitman FG
Eur Neuropsychopharmacol; 2004 Aug; 14(4):301-6. PubMed ID: 15163440
[TBL] [Abstract][Full Text] [Related]
18. The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia.
Walsh JK; Deacon S; Dijk DJ; Lundahl J
Sleep; 2007 May; 30(5):593-602. PubMed ID: 17552374
[TBL] [Abstract][Full Text] [Related]
19. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia.
Parrino L; Smerieri A; Giglia F; Milioli G; De Paolis F; Terzano MG
Clin Neuropharmacol; 2008; 31(1):40-50. PubMed ID: 18303490
[TBL] [Abstract][Full Text] [Related]
20. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia.
Walsh JK; Perlis M; Rosenthal M; Krystal A; Jiang J; Roth T
J Clin Sleep Med; 2006 Jan; 2(1):35-41. PubMed ID: 17557435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
